合成化合物动物体内抗肿瘤实验方法研究进展

进行了动物体内抗肿瘤活性研究的多为天然药物,但其来源有限;虽然用于抗肿瘤研究的合成化合物种类较多,但对于其在动物体内抗肿瘤研究又相对偏少,所以,合成化合物抗肿瘤体内研究已经成为研究热点之一。本文对合成化合物抗肿瘤作用机制、体内肿瘤模型建立方法和体内抑瘤实验研究等方面的研究进展进行了评述,并通过大量实验数据对合成化合物毒性评价方法、抑瘤基本观察指标测定、氧化损伤相关酶活力的测定方法、组织病理学评价方法等体内抑瘤实验的评价标准和方法进行了详细总结,提出了合成化合物在体内动物抗肿瘤实验研究方法中亟待解决的问题,为新型抗肿瘤合成化合物体内药学活性研究提供有益的参考。     

铑配合物的抗肿瘤活性及其作用机制研究

自从Rosenberg等人发现顺铂具有抗肿瘤活性以来，金属配合物的抗肿瘤活性引起了人们的广泛关注。本文综述了近年来铑配合物抗肿瘤活性的研究进展，并对铑配合物的抗肿瘤机制和构效关系进行了探讨，为进一步寻找高效低毒和抗肿瘤谱广的新药物揭示了可循的途径。     

Naphthalimides and analogues as antitumor agents: A review on molecular design,bioactivity and mechanism of action

Our research improves the structure diversity of naphthalimide antitumor agents and distinct variances of antitumor targets and mechanism of action.     

非铂类金属抗肿瘤药物的研究进展

自从顺铂被发现具有抗肿瘤活性以来,金属抗肿瘤药物得到了飞速的发展,一些非铂类金属的化合物也相继被发现具有一定的抗肿瘤活性。与铂类金属药物相比,非铂类金属抗肿瘤药物的发展相对缓慢,但也取得了一定的成果。本文主要就一些已经进入临床试验阶段的非铂类抗肿瘤药物的研究进展作一简述。     

Design of peptide–dendrimer conjugates with tumor homing and antitumor effects

Development of drug delivery systems for cancer therapy is a crucial issue. Previously, some peptides were designed as tumor homing cell-penetrating peptides with antitumor activities. In this study, dual function dendrimers with tumor targeting activities and antitumor effects were designed using the tumor targeting CPP44 peptide for acute myelogenous leukemia (AML) and the antitumor p16^INK4a peptide. Two types of peptide–dendrimer conjugates were synthesized. One was a CPP44-linked p16^INK4a peptide-conjugated dendrimer (tandem linked dendrimer) and the other was a dendrimer conjugated with separate CPP44 and p16^INK4a peptides (parallel linked dendrimer). In addition, a peptide cathepsin B substrate was linked to the antitumor p16^INK4a peptide to release it from the carriers. These peptide–dendrimer conjugates produced more effective antitumor effects than a CPP44-linked p16^INK4a peptide. The parallel linked dendrimer showed less association with AML cells than the tandem linked dendrimer, but had greater antitumor effects. This suggested that both cellular uptake and antitumor peptide cleavage affected the antitumor activities of dual functional peptide-conjugated dendrimers.     

抗肿瘤铂配合物的研究进展

综述了30年来抗肿瘤铂配合物的研究进展,重点介绍了违背原有构效关系的铂的新型配合物的设计思想及研究情况,包括铂(Ⅳ)配合物、反式铂配合物、铂高分子配合物等。     

Preparation of DHAQ-loaded PLA-PLL-RGD Nanoparticles and Comparison of Antitumor Efficacy to Hepatoma and Breast Carcinoma

This study researches the synthesis of Arginine-Glycine-Asparti (RGD) peptide modification of copolymer: poly (lactic acid-co-_L-lysine) (PLA-PLL-RGD) and the preparation of mitoxantrone (DHAQ)-loaded PLA-PLL-RGD nanoparticles (DHAQ-NP), and evaluates antitumor efficacy of exercise and DHAQ-NP in hepatoma and breast carcinoma. The experimental findings demonstrate that DHAQ-NP group have more significant antitumor efficacy than DHAQ group in hepatoma-bearing mice and breast carcinoma-bearing mice. Compared with DHAQ-NP group, the antitumor efficacy of Exercise+DHAQ-NP group are significantly lower in breast carcinoma-bearing mice. However, the antitumor efficacy of Exercise+DHAQ-NP group have no significant change in hepatoma-bearing mice. This suggests that the same exercise intensity can cause different antitumor efficacies for different tumors undergoing targeted therapies.     

主链含酪氨酸的聚磷酸酯抗肿瘤药物的研究

通过含酪氨酸的聚磷酸酯与药物分子进行大分子反应，制备了含５－氟尿嘧啶或氨甲蝶呤的聚磷酸酯。所得聚磷酸酯均具有两亲性，部分聚磷酸酯在水中能形成胶束。研究了这些聚合物的体外降解和释药性能，体外抗肿瘤实验表明，有些聚磷酸酯药物具有较强的抗肿瘤活性。     

氟尿嘧啶自旋标记衍生物的合成与抗肿瘤活性

稳定氮氧自由基作为某些抗癌药物的载体,不仅能提高药物对癌细胞的选择性,而且为借助电子自旋共振(ESR)技术研究药物的作用机理和代谢提供了一种新手段。在前文中,我们报道了几种5-氟尿嘧啶的自旋标记衍生物。作为这一工作的继续,本文报道一系列新的氟尿嘧啶自旋标记衍生物10_(a—c)、11_(a—c)和12_(a—c)的合成及其抗肿瘤活性的研究。     

Synthesis and antitumor activities of alkyl-1,4-butanediamine Pt(II) complexes having seven-membered ring structure

Novel alkyl-1,4-butanediamine Pt(II) complexes having a seven-membered ring structure were synthesized and characterized by fast atom bombardment mass and infrared spectra and elemental analysis. Their antitumor activities in vivo toward lymphoid leukemia L1210 and Lewis lung carcinoma LL were studied in the case where the leaving group was either dichloride or cyclobutane-1,1-dicarboxylate. 1,4-Butanediamine Pt(II) complexes (seven-membered ring) showed higher antitumor activities than those of ethylenediamine Pt(II) (five-membered ring) and 1,3-propanediamine Pt(II) (six-membered ring) complexes toward L1210 for both leaving groups. Alkyl-1,4-butanediamine Pt(II) complexes showed high antitumor activities toward L1210, except for 1,1-dimethyl-1,4-butanediamine Pt(II) complexes. In particular, 2,2-dimethyl-1,4-butanediamine and 2,3-dimethyl-1,4-butanediamine Pt(II) complexes exhibited excellent antitumor activities with T/C% values higher than 300. None of the dichloro Pt(II) complexes showed antitumor activities toward LL, but the cyclobutane-1,1-dicarboxylato Pt(II) complexes, which were moderately active toward L1210 with T/C% values around 200, also showed high antitumor activities toward LL with T/C% values of more than 200. Alkyl-1,4-butanediamine Pt(II) complexes with a seven-membered ring structure were found to be stable and to have antitumor activities in vivo.     

Design,synthesis and biological evaluation of E-ring modified evodiamine derivatives as novel antitumor agents

A series of novel E-ring modified evodiamine derivatives were designed and synthesized as antitumor agents. Their capacity to interfere with the catalytic activity of topoisomerase Ⅰ and Ⅱ was evaluated by the relaxation assay. In vitro antitumor activity results revealed that compound 12 showed good antitumor activity with a broad spectrum. Its binding modes with topoisomerase Ⅰ and Ⅱ were clarified by molecular docking.     

Acridine derivatives. V. Synthesis and P388 antitumor activity of the novel 9-anilino-2,3-ethylenedioxyacridines

A new class of deoxyribonucleic acid (DNA)-intercalating antitumor agents, novel 9-anilino-2,3-ethylenedioxyacridines (five compounds) have been synthesized and evaluated for activity against P388 leukemia in vivo. A few of them possessed the same potency of antitumor activity as amsacrine (m-AMSA) which is an important antitumor agent in clinical use.     

Synthesis and antitumor activity of benzimidazolyl-1,3,5-triazine and benzimidazolylpyrimidine derivatives

Triamino-substituted 1,3,5-triazine and pyrimidine derivatives were synthesized and tested for antitumor activities using some human cancer cell lines and murine leukemia cell lines. All the compounds having benzimidazolyl and morpholino groups as substituents on the 1,3,5-triazine ring showed antitumor activity. Pyrimidine derivatives having the same groups as substituents also showed antitumor activity. Among them, the compounds having 1-benzimidazolyl, morpholino and cis-2,3-dimethylmorpholino groups as substituents on the 1,3,5-triazine ring or pyrimidine ring exhibited the most potent antitumor activity, and these compounds exhibited no or very weak aromatase inhibitory activity. In contrast, the compounds having imidazolyl group instead of benzimidazolyl group as a substituent on the 1,3,5-triazine ring showed a potent aromatase inhibitory activity.     

Synthesis and antitumor activities of structure-related small molecular compounds of gambogic acid

Through simplifying the complicated skeleton of the natural product gambogic acid, two series derivatives of chromone and xanthone were synthesized and examined for their antitumor activities against several cancer cells in vitro by MTT method. The results showed that appropriate introduction of prenyl group to the small molecular compounds could elevate their antitumor activities. The structure-activities relationship of synthesized compounds certified that the bridgecore in gambogic acid was very important for keeping its antitumor activities.     

Synthesis and Antitumor Activity of 7-Substituted Derivatives of Homocamptothecin

Camptotecin is the parent of an important class of anticancer agents which, can selectively poison the ubiquitous nuclear enzyme topoisomerase. Water soluble camptothecin analogues such as topotecan and irinotecan are already approved for clinical uses in…     

Synthesis and antitumor activity of novel 10-amino acids ester homocamptothecin analogues

Nine racemic homocamptothecin derivatives were synthesized and in vitro antitumor activities were evaluated by standard MTT method. The results showed that some of the compound had higher antitumor activity than iritecan.     

基于硒元素的抗癌药物研究进展

硒是人体必需的一种微量元素,对维持人体正常生理功能起着关键作用,具有广泛的生物学活性,并通过多种机制发挥抗肿瘤作用,缺硒与冠心病、贫血症、关节炎、糖尿病等有着密切的关系。本文对硒的性质、抗肿瘤作用机制、含硒抗肿瘤药物的分类以及有机硒抗肿瘤药物等方面进行了介绍,以期提高人们对含硒抗肿瘤药物的准确认识,促进含硒抗肿瘤药物的...     

黄酮类化合物结构修饰及抗肿瘤活性研究进展

我国天然药物和中药资源丰富,种类繁多,可作为先导化合物进行修饰以提高可成药性。其中,黄酮类化合物是自然界中一种常见的天然多酚类化合物,在抗肿瘤方面具有其独特的生物活性;对其进行结构修饰与改造,可提高黄酮类化合物的生物利用度和抗肿瘤活性。本文通过查阅并整理近几年国内外的黄酮类化合物的相关文献,对黄酮类化合物的母核位点进行结构修饰与改造所得的101个黄酮类衍生物及其抗肿瘤活性及作用机制进行综述,同时讨论了构效关系,以期为黄酮类衍生物的结构修饰和抗肿瘤研究提供参考和帮助。     

有机和有机金属多酸化合物生物活性研究

抗肿瘤活性;有机和有机金属多酸化合物生物活性研究     

铂（Ⅱ）类抗肿瘤药物

自顺铂临床用于抗肿瘤药物以来,在铂配合物中寻找新的药物已成为研究的热点,现在已有顺铂、卡铂和奥沙利铂在广泛应用于临床。根据经典的构效关系,上千个新的铂类化合物被设计与合成出来。我们综述了铂（Ⅱ）类抗肿瘤药物近五年的研究状况,介绍了包括含有生物活性基团的铂（Ⅱ）配合物,具有空间位阻的铂（Ⅱ）配合物,反式铂（Ⅱ）配合物,含S、P配位原子铂（Ⅱ）配合物和多核铂（Ⅱ）配合物,总结了这些化合物的抗肿瘤机理、活性。